Medicines Licensing Assessor Services
Bidders should access the Health Family e-tendering portal to access the full-set of requirements and to submit any tender. Interested suppliers https://atamis-1928.my.site.com/s/Welcome
The submission route named on the official notice.
This is a large award for Research & Development — above three-quarters of comparable contracts. Based on 20,405 valued Research & Development tenders in our corpus.
The Medicines and Healthcare products Regulatory Agency is the regulator of medicines, medical devices and blood components for transfusion in the UK.
MHRA carries out a wide range of activities to fulfil its role as a patient safety regulator.
This includes carrying out assessments of the safety, quality and efficacy of medicines, assessing the safety of proposed clinical trials of medicines and medical devices, inspecting the premises of those manufacturing, supplying or distributing medicines and monitoring the ongoing safety of all medical products, taking swift action where necessary to prevent harm to patients.
The MHRA also engages with companies within the regulated sector to provide specific, scientific advice on the development of products.
The aim of such advice is to ensure the developer understands the requirements of the regulator, ensuring that the developer can provide the required information to support a properly informed assessment.
With a wide range of critical deliverables, MHRA is seeking opportunities to add to its traditional in-house expertise through the establishment of additional sources of both capacity and capability.
These will enable MHRA to deliver innovative, new and improved services at increased pace, safeguarding public health and supporting the growth of life sciences in the UK.
MHRA is seeking suppliers with the capacity and capability to deliver assessments of complex clinical and non-clinical regulatory data and provide carefully evidenced judgements within an MHRA assessment and quality assurance framework.
Such assessments may relate to marketing authorisation applications, clinical trial applications and a variety of other compliance activities.
Deployment of supplier resources will be on a flexible basis to enable MHRA greater discretion in flexing established capacity as needed to support increased growth in UK life sciences through new and improved advice and support services.
To achieve this ambition, MHRA wishes to establish a framework of specialist providers, which cover 3 Lots.
Up to four suppliers, who meet the minimum criteria, may be awarded a place on each Lot.
Lot 1: Pharmaceutical Assessment: Assessment of pharmaceutical/quality data (in compliance with Module 3 and Module 2 (sections relevant to Quality) of the Common Technical Document).
Lot 2: Medical Assessment: Assessment of clinical, statistical and clinical pharmacology data (in compliance with Module 5 and Module 2 (sections relevant to Clinical) of the Common Technical Document).
Lot 3: Non-Clinical Assessment: Assessment of non-clinical data (in compliance with Module 4 of the Common Technical Document).
What the supplier must deliver
The MHRA also engages with companies within
The MHRA also engages with companies within the regulated sector to provide specific, scientific advice on the development of products.
The aim of such advice is
The aim of such advice is to ensure the developer understands the requirements of the regulator, ensuring that the developer can provide the required information to support a properly informed assessment.
These will enable MHRA to deliver innovative
These will enable MHRA to deliver innovative, new and improved services at increased pace, safeguarding public health and supporting the growth of life sciences in the UK.
MHRA is seeking suppliers with the capacity
MHRA is seeking suppliers with the capacity and capability to deliver assessments of complex clinical and non-clinical regulatory data and provide carefully evidenced judgements within an MHRA assessment and quality assurance framework.
Deployment of supplier resources will be on
Deployment of supplier resources will be on a flexible basis to enable MHRA greater discretion in flexing established capacity as needed to support increased growth in UK life sciences through new and improved advice and support services.
Derived from the notice text — always confirm against the original documents.
What it takes to bid this
Typical UK bid effort for the £10m+ band — an estimate, not a quote.
Qualify & bid/no-bid ~10% · SQ / PQQ ~20% · Written response ~55% · Review & presentation ~15%
Typical for this category — confirm against the ITT pack
- Show at bidComparable references / case studies
- Hold at bidFinancial standing (accounts, often ~2× contract value turnover)
- Hold at bidInsurance cover (PL / EL, often PI)
- Show at bidSocial value commitments
Hold at bid = pass/fail conditions of participation. Show at bid = scored in the quality response. Plan for delivery = contract obligations from day one.
Make the case to bid
Reveal who to approach at MHRA, and generate a go-to-market strategy from their news, accounts and people.
The full intelligence dossier
Our agent reads MHRA’s accounts, hunts live signals, finds the people who decide — and hands you a bid strategy plus a go-to-market influence plan, including what your team should post this week. You approve every paid step.
Ask me about this tender, the buyer, who wins their work, or whether you should bid.
- OCID
- ocds-h6vhtk-060643
- Stage
- tender · Open
- Source
- Find a Tender
- Buyer ref
- 062516-2026
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Research & Development
MHRA’s tender network
Assembling the network…